文献速递血脂与心血管预防

Lepodisiran对脂蛋白(a)氧化磷脂的影响:靶向Lp(a)的长效siRNA

Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a).
PubMed 文献 · J Am Coll Cardiol · 2026-08-31

本研究为随机安慰剂对照2期试验的事后分析,纳入213例接受安慰剂或Lepodisiran 16、96、400 mg的受试者,评估OxPL-apo(a)和OxPL-apoB水平变化及其与Lp(a)降低的相关性。结果显示Lepodisiran可持续降低OxPL-apoB和OxPL-apo(a),且与Lp(a)降低相关,为正在进行的3期心血管结局试验提供生物学依据,但尚未确立临床获益。

要点

  • Lepodisiran 400 mg使OxPL-apo(a)第240天降低94.2%,第360天降低80.7%。
  • OxPL-apo(a)变化与Lp(a)降低的相关性优于OxPL-apoB。
  • OxPL变化与hs-CRP无显著相关,提示独立于系统性炎症。

核心结论

  • Lepodisiran可持续降低OxPL-apoB和OxPL-apo(a)水平,且与Lp(a)降低相关。
  • 这些发现为正在进行的Lepodisiran 3期心血管结局试验提供额外生物学依据,但未确立临床获益。

研究设计与样本

  • 随机、安慰剂对照2期试验的事后分析,试验在全球66个中心纳入320例受试者。
  • 本次分析纳入213例在基线及第180天接受安慰剂或Lepodisiran 16、96、400 mg且基线和第240、360天有OxPL测量的受试者。
  • 评估安慰剂校正的OxPL-apo(a)和OxPL-apoB自基线变化百分比,及与Lp(a)变化的相关性。

主要发现

  • 第240天OxPL-apo(a)安慰剂校正几何均值变化百分比:16 mg组-21.9%(95%CI:-45.0%至11.0%),96 mg组-65.1%(95%CI:-73.8%至-53.6%),400 mg组-94.2%(95%CI:-95.7%至-92.2%)。
  • 第240天OxPL-apoB变化百分比:16 mg组-39.5%(95%CI:-51.2%至-25.0%),96 mg组-76.9%(95%CI:-80.6%至-72.5%),400 mg组-88.5%(95%CI:-90.4%至-86.3%)。
  • 第360天OxPL-apo(a)变化百分比:16 mg组-23.7%(95%CI:-47.0%至9.8%),96 mg组-41.6%(95%CI:-56.4%至-21.6%),400 mg组-80.7%(95%CI:-85.7%至-73.9%)。
  • 第360天OxPL-apoB变化百分比:16 mg组-30.6%(95%CI:-46.4%至-10.2%),96 mg组-57.1%(95%CI:-65.2%至-47.2%),400 mg组-79.9%(95%CI:-83.8%至-75.2%)。

临床怎么用

  • Lepodisiran可显著降低Lp(a)颗粒上的氧化磷脂,支持其作为Lp(a)靶向治疗的作用机制。
  • 目前尚不能基于OxPL降低推荐临床使用Lepodisiran,需等待3期心血管结局试验结果。

局限性

  • 为2期试验的事后分析,样本量有限(213例)。
  • 未评估临床终点,不能确立心血管获益。
  • OxPL变化与hs-CRP无显著相关,但未报告其他炎症标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein(a) [Lp(a)] is a largely genetically determined causal risk factor for atherosclerotic cardiovascular disease and aortic stenosis, likely mediated in part by oxidized phospholipids (OxPL) bound to apolipoprotein(a) [apo(a)] and apolipoprotein B (apoB). Lepodisiran, an extended-duration small interfering RNA demonstrated large and durable reductions in Lp(a) in a phase 2 trial. OBJECTIVES: The purpose of this study was to assess effects of lepodisiran on OxPL-apo(a) and -apoB levels, their relationship to Lp(a) and apoB lowering, whether reductions are proportional to particle reduction, and whether changes correlate with biomarkers of systemic inflammation. METHODS: The randomized, placebo-controlled phase 2 trial enrolled 320 participants at 66 global centers. The current post hoc analysis included 213 of 320 participants who received placebo or lepodisiran 16, 96, or 400 mg at baseline and day 180 and had OxPL levels measured at baseline, day 240, and day 360. Placebo-adjusted percent change from baseline in OxPL-apo(a) and -apoB were assessed. Correlations between percent change in Lp(a), OxPL-apo(a), and -apoB were also determined. RESULTS: Median baseline OxPL-apo(a) and -apoB levels were 122.0 nmol/L (Q1, Q3: 105.1, 137.7 nmol/L) and 27.7 nmol/L (Q1, Q3: 22.5, 36.2 nmol/L) for all participants. Placebo-adjusted geometric mean percent changes in OxPL-apo(a) at day 240 were -21.9% (95% CI: -45.0% to 11.0%), -65.1% (95% CI: -73.8% to -53.6%), and -94.2% (95% CI: -95.7% to -92.2%) in the 16-, 96-, and 400-mg dose groups, respectively. Percent changes in OxPL-apoB at day 240 in these dose groups were -39.5% (95% CI: -51.2% to -25.0%), -76.9% (95% CI: -80.6% to -72.5%), and -88.5% (95% CI: -90.4% to -86.3%), respectively. The percent change in OxPL-apo(a) at day 360 were -23.7% (95% CI: -47.0% to 9.8%), -41.6% (95% CI: -56.4% to -21.6%), and -80.7% (95% CI: -85.7% to -73.9%) in the 16-, 96-, and 400-mg dose groups, respectively. The percent changes in OxPL-apoB at day 360 in these dose groups were -30.6% (95% CI: -46.4% to -10.2%), -57.1% (95% CI: -65.2% to -47.2%), and -79.9% (95% CI: -83.8% to -75.2%), respectively. Percent change in OxPL-apo(a) correlated more closely than OxPL-apoB with percent change in Lp(a) than did OxPL-apoB. There was no significant correlation between changes in high-sensitivity C-reactive protein and OxPL. CONCLUSIONS: Lepodisiran produced sustained reductions in OxPL-apoB and OxPL-apo(a) levels that correlated with Lp(a) lowering. These findings provide additional biological rationale for the ongoing lepodisiran phase 3 cardiovascular outcomes trial, but do not establish clinical benefit. (A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]; NCT05565742).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nissen SE, Navar AM, Krege JH, et al. Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a). J Am Coll Cardiol. 2026. PMID: 42671367. doi:10.1016/j.jacc.2026.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。